Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Halozyme Therapeutics Inc Presents PEGPH20 Phase 1b Clinical Trial Data At European Cancer Congress 2013


Monday, 30 Sep 2013 08:15am EDT 

Halozyme Therapeutics, Inc announced that mature patient progression free survival (PFS) and ongoing overall survival (OS) data from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination with gemcitabine for the treatment of patients with stage IV metastatic pancreatic cancer. In the trial, both PFS and OS data suggest a potential clinical benefit of using PEGPH20 with gemcitabine in patients with high levels of tumor associated hyaluronan (HA). These results are being presented at European Cancer Congress 2013 (ECCO-ESMO-ESTRO) in a poster session at 14:00 CEST (Hall 4, Abstract #2598). Early response rates from this trial were previously presented at the 2013 American Society of Clinical Oncology (ASCO) Annual meeting in June 2013. 

Company Quote

8.87
0.1 +1.14%
26 Nov 2014